Research ArticleArticle
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar and Sabina Ciciriello
The Journal of Rheumatology August 2021, jrheum.201551; DOI: https://doi.org/10.3899/jrheum.201551
Hedley Griffiths
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Tegan Smith
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Christopher Mack
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Jo Leadbetter
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Belinda Butcher
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Mustafa Acar
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
Sabina Ciciriello
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley@brservice.com.au. Accepted for publication July 22, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar, Sabina Ciciriello
The Journal of Rheumatology Aug 2021, jrheum.201551; DOI: 10.3899/jrheum.201551
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar, Sabina Ciciriello
The Journal of Rheumatology Aug 2021, jrheum.201551; DOI: 10.3899/jrheum.201551